Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.51 |
| ▸ | FNTA | P49354 | 5/20 | 0.43 |
| ▸ | FNTB | P49356 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23318279 | 0.73 | RORC (0.44) | FNTAFNTBKDM4E | |
| SCHEMBL25446125 | 0.71 | TFPI2 (0.46) | CREBBPKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL3814387 | 0.70 | KRAS (0.40) | CREBBPLMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL23318379 | 0.68 | KRAS (0.37) | LMNAKMT2AMEN1SMN1; SMN2BLM | |
| SCHEMBL21392878 | 0.68 | KMT2A (0.40) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21392862 | 0.68 | KDM4E (0.38) | LMNAKMT2AMEN1SMN1; SMN2BLM | |
| SCHEMBL28620498 | 0.68 | CREBBP (1.00) | CREBBPLMNAALDH1A1KDM4E | |
| SCHEMBL27419359 | 0.67 | PLK1 (0.60) | KMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL23318458 | 0.67 | ALDH1A1 (0.51) | LMNAKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7850828 | 0.65 | KMT2A (0.47) | FNTAFNTBLMNAKDM5BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| WO-2021087096-A1 | P53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | CREBBP 748/4885FNTA 1342/4885FNTB 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.